Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315182 · ClinicalTrials.gov registry record · Phase 1
Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
A Phase 1 study, sponsored by Abeona Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03315182 is a Phase 1 study that was terminated before completion, run by Abeona Therapeutics. The registered enrollment target is 11 participants.
The verdict
NCT03315182, a Phase 1 study, was terminated before completion, sponsored by Abeona Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Open-label, dose-escalation clinical trial of rAAV9.CMV.hNAGLU injected intravenously through a peripheral limb vein
Interventions
- BIOLOGICAL rAAV9.CMV.hNAGLU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2022-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315182
The ClinicalTrials.gov registry entry for NCT03315182 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abeona Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rAAV9.CMV.hNAGLU is the first listed.
NCT03315182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03315182 about?
NCT03315182 is a clinical study titled "Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB". Open-label, dose-escalation clinical trial of rAAV9.CMV.hNAGLU injected intravenously through a peripheral limb vein
What is the current status of trial NCT03315182?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-10-16. Estimated completion is 2022-04-07.
What interventions are being tested in trial NCT03315182?
The interventions under investigation include: rAAV9.CMV.hNAGLU (BIOLOGICAL).
Who is sponsoring clinical trial NCT03315182?
This trial is sponsored by Abeona Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.